Markets:

Overview

News

Currencies

International

Treasuries

MAIA Biotechnology, Inc. Common Stock (NY:MAIA)

1.970 +0.060 (+3.14%)

Official Closing Price Updated: 8:00 PM EST, Feb 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about MAIA Biotechnology, Inc. Common Stock

< Previous 1 2 3 4 Next >

MAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer Patients

March 06, 2024

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology CEO Details Immuno-Oncology Cancer Treatment Candidates and Development Pipeline in Letter to Shareholders

March 05, 2024

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology Announces Publication in Nature Communications on Positive Effects of THIO for Potential Treatment of Small Cell Lung Cancer

February 07, 2024

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology Reports Positive Phase 2 Clinical Trial Data On Its Treatment For Non-Small Cell Lung Cancer

October 31, 2023

Via ACCESSWIRE

MAIA Biotechnology Announces Publication of International PCT Patent Application Covering Anticancer Telomere-Targeting Compounds

January 24, 2024

From MAIA Biotechnology

Via Business Wire

MAIA Biotechnology Provides Positive Phase 2 Clinical Updates for Lead Anticancer Agent and Outlines Targeted Milestones for 2024

January 17, 2024

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology to Present at Biotech Showcase 2024 on January 9, 2024

January 05, 2024

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology Announces Dose Selection in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer

December 19, 2023

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology Announces Closing of $4 Million Registered Direct Offering

November 17, 2023

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology (NYSE: MAIA) Has Received FDA Orphan Drug Designation For THIO As A Treatment For Most Aggressive Brain Cancer

November 17, 2023

Via ACCESSWIRE

MAIA Biotechnology Announces $4 Million Registered Direct Offering

November 15, 2023

From MAIA Biotechnology, Inc.

Via Business Wire

FDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO as a Treatment for Glioblastoma

November 10, 2023

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology Reports Third Quarter 2023 Financial Results and Highlights Recent Development Progress for Anticancer Asset THIO

November 07, 2023

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology Reveals Higher Anticancer Potency of Telomere-Targeting Compounds Derived from THIO

October 30, 2023

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology Announces 100% Disease Control in Second-Line Non-Small Cell Lung Cancer Demonstrating Impressive Positive Preliminary Efficacy Data for Ongoing THIO-101 Phase 2 Trial

October 24, 2023

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology to Present Preliminary Safety and Efficacy Data from THIO-101 Phase 2 Clinical Trial at European Society for Medical Oncology Congress 2023

October 19, 2023

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology's THIO Emerges As Potential Breakthrough In Pediatric Brain Cancer Therapy

October 17, 2023

Via ACCESSWIRE

MAIA Biotechnology to Present Latest Findings for Second Generation THIO Program at Turkish Biochemical Society’s International Biochemistry Congress 2023

October 17, 2023

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology Reveals New Data Showing THIO’s Potent Anticancer Activity in Aggressive Pediatric Brain Cancer

October 12, 2023

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology Accelerates Enrollment in THIO-101 Phase II Clinical Trial as Efficacy Is Observed in Dosed Patients

October 10, 2023

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology Announces Potent Anticancer Activity of THIO in Gliomas

October 10, 2023

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology Announces FDA Clearance of IND Application for THIO, a First-in-Class Telomere Targeting Agent for the Treatment of Non-Small Cell Lung Cancer

October 03, 2023

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology Announces Share Repurchase Program

September 28, 2023

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology Reports Second Quarter 2023 Financial Results and Provides Updates for THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer

August 08, 2023

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology Reports Updates on Disease Control Rates for THIO-101 Phase 2 Trial for Advanced Non-Small Cell Lung Cancer

July 11, 2023

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology Reports Updates on Preliminary Survival Data for THIO-101 Phase 2 Trial for Advanced Non-Small Cell Lung Cancer

July 10, 2023

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology Announces Updates in Enrollment in Phase II Clinical Trial: THIO-101 Has Enrolled 29 Patients

June 20, 2023

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology Files Second Patent For New Telomere-Targeting Molecules Program

June 07, 2023

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 08, 2023

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology, Inc. Announces Closing of Public Offering

April 27, 2023

From MAIA Biotechnology, Inc.

Via Business Wire

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

MAIA Biotechnology, Inc. Common Stock (NY:MAIA)

Press Releases about MAIA Biotechnology, Inc. Common Stock

Starting at $3.75/week.

Subscribe Today